Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Matthew J. Flick · UNIV OF NORTH CAROLINA CHAPEL HILL · 2022 · $551,675 — SUMMARY Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2; CoV2) is the first highly pathogenic and highly transmissible human coronavirus that is the causative agent for the worldwide COVID-19 pandemic. As of November 2020, 50 million cases of CoV2 infection worldwide and 1.25 million dea…
Monica Kraft · UNIVERSITY OF ARIZONA · 2022 · $1,431,641 — In this AADCRC program renewal, we will focus on three critical and understudied innate immune factors and how they impact viral infections in asthma: the anionic phospholipids of surfactant (palmitoyl- oleoyl-phosphatidylglycerol, POPG, and phosphatidylinositol, PI), Toll interacting protein (Tolli…
Alexander Minchev Tsankov · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2022 · $126,750 — PROJECT SUMMARY COVID-19 disease, caused by the novel coronavirus SARS-CoV-2, is a global health threat due to its rapid spread, morbidity, and mortality. It is estimated that at least 25% of severe COVID-19 disease survivors experience persistent respiratory complications. This underscores the need…
JOHN P COOKE · BOSTON UNIVERSITY MEDICAL CAMPUS · 2022 · $665,322 — ABSTRACT Determinants of COVID19-induced venous thrombosis and targeted therapy assessed with bioengineered Vein-Chip Challenge: Increasing evidence shows that SARS-CoV-2, which is the novel coronavirus that causes COVID- 19, is able to trigger the formation of blood clots within the veins of patien…
Spyridon Stavrou · STATE UNIVERSITY OF NEW YORK AT BUFFALO · 2022 · $239,250 — A viral pathogen associated with severe pneumonia was recently identified as the cause of a global pandemic that has resulted in the death of over two million people. This viral pathogen was later classified as a coronavirus that was subsequently named Severe Acute Respiratory Syndrome Coronavirus 2…
Florian Douam · BOSTON UNIVERSITY MEDICAL CAMPUS · 2022 · $201,700 — Project Summary We are in the midst of an unprecedented, modern pandemic as a result of the evolution of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019. SARS-CoV-2 is one of three known coronaviruses that can replicate in the lower respiratory tract and cause pneumoni…
Ivan Marazzi · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2022 · $794,868 — PROJECT SUMMARY Infection causes inflammation, which contributes to pathogen clearance and survival of the host organism. However, failure to regulate the inflammatory response can often lead to multiple organ damage and lethality for the host. In the current COVID-19 pandemic caused by the severe a…
John Schneekloth · DIVISION OF BASIC SCIENCES - NCI · 2022 · $324,711 — Traditional drug screening strategies are based on targeting coronavirus-related proteins (e.g., RdRp, Mpro, and 3CLpro) and receptors (e.g. ACE2). In addition to virus-coded proteins, RNA structures within the SARS-CoV-2 genome also regulate essential functions and are potentially at…
Liang Cao · DIVISION OF BASIC SCIENCES - NCI · 2022 · $822,832 — Related to the specific biomarker goals above, we conducted various studies to support biomarker driven early-stage drug development: 1. Application of new or novel biomarkers in early-stage trials of highly unique therapeutic agents. A) We supported correlative marker investigations …
Julian A Symons · HACKENSACK UNIVERSITY MEDICAL CENTER · 2022 · $4,228,031 — Project Summary/Abstract: Development of ALG-097431 as a Broad-Spectrum SARS-CoV-2 3CLpro Inhibitor Inhibition of viral proteases with small molecule drugs is a proven successful therapeutic approach and is currently used for the treatment of HCV and HIV infection. The SARS-CoV-2 main, 3-chymotrypsi…
Aaron Gregory Schmidt · WASHINGTON UNIVERSITY · 2022 · $1,934,136 — Project Summary The global pandemic caused by Severe Acute Respiratory Syndrome virus 2 (SARS-CoV-2) coronavirus (CoV) has highlighted the need to develop next-generation viral vaccines that offer protection against future Sarbecoviruses and Merbecoviruses of concern. One approach is to implement st…
Noha Shawky · UNIVERSITY OF MISSISSIPPI MED CTR · 2022 · $268,835 — Polycystic ovary syndrome (PCOS), the most common endocrine disorder in young women, is characterized by hyperandrogenemia and metabolic dysfunction. PCOS women who become pregnant may have offspring born with low birth weight (LBW), associated with increased risk for cardiovascular (CV) disease (…
DIRK HOMANN · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2022 · $418,419 — ABSTRACT The possibility that infection with SARS-CoV-2 may trigger diabetes emerged as a concern in mid 2020. We have addressed this issue by developing a research roadmap that identified complementary areas of investigation according to several broad topics in the realm of relevant basic biomedica…
Sachiko Homma · BOSTON UNIVERSITY MEDICAL CAMPUS · 2022 · $270,903 — PROJECT SUMMARY As the COVID-19 pandemic continues, managing post COVID-19 long-haul symptoms have become the next level challenge. Persistent skeletal muscle aches (myalgia) and fatigue are among the most common symptoms reported by COVID-19 long haulers who have symptoms beyond 20 weeks. The myalg…
Michal Toborek · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · 2022 · $148,376 — ABSTRACT COVID-19, which is caused by Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2), has resulted in devastating morbidity and mortality worldwide due to lethal pneumonia and respiratory distress. In addition, the central nervous system (CNS) is well documented to be a target of SARS…
Cynthia Ann Derdeyn · EMORY UNIVERSITY · 2022 · $195,625 — SUMMARY Clinical sequelae of COVID-19 patients include not only acute respiratory distress syndrome (ARDS), but also often acute kidney injury and heart failure. These pathologies share endothelial activation as a common underlying early response to injury, and endothelial cells express high levels …
MARY ANN Y JABRA-RIZK · UNIVERSITY OF MARYLAND BALTIMORE · 2022 · $231,750 — PROJECT SUMMARY Recently, individuals with COVID-19 were found to harbor replicating SARS-CoV-2 inside salivary epithelial cells resulting in inflammation, architectural distortion, and atrophy of minor and major salivary glands. We have previously demonstrated the importance of histatin-5, a secret…
Takako Araki · UNIVERSITY OF MINNESOTA · 2022 · $392,800 — PROJECT SUMMARY COVID-19–related extra-pulmonary damage is common and may even be observed in patients with mild COVID- 19 symptoms. There is an urgent and immediate need to establish optimal post-infection health care strategies for these patients, yet mechanisms underlying their appearance remain …
Jack Henkin · ANGIOTENSIN THERAPEUTICS, INC. · 2022 · $299,842 — Project Summary Systemically administered soluble native ACE2 is currently tested as a viral decoy to prevent SARS-CoV-2 cell entry in COVID-19 patients. This soluble ACE2 protein, however, has a short half-life and limited bioavailability in the lung, especially at the target sites for SARS-CoV-2 e…
George Ueda · UNIVERSITY OF WASHINGTON · 2022 · $127,929 — Broader Impacts: The current COVID-19 outbreak is a global pandemic with over 45 million cases and 1,200,000 deaths officially reported. Epidemiological data emerging from Italy indicate that 40-96% of COVID- 19 patients admitted into the hospital develop ARDS and sepsis. Developing a functional tre…